Literature DB >> 18829791

Procalcitonin in young febrile infants for the detection of serious bacterial infections.

Vincenzo Maniaci1, Andrew Dauber, Scott Weiss, Eric Nylen, Kenneth L Becker, Richard Bachur.   

Abstract

OBJECTIVES: The objectives of the study were (1) to study the test performance of procalcitonin for identifying serious bacterial infections in febrile infants <or=90 days of age without an identifiable bacterial source and (2) to determine an optimal cutoff value to identify infants at low risk for serious bacterial infections.
METHODS: A prospective observational study was performed with febrile infants <or=90 days of age presenting to an urban, pediatric, emergency department. Serum procalcitonin levels were measured by using an automated high-sensitivity assay. An optimal procalcitonin cutoff value was selected to maximize sensitivity and negative predictive value for the detection of serious bacterial infections. Infants were classified as having definite, possible, or no serious bacterial infections.
RESULTS: A total of 234 infants (median age: 51 days) were studied. Thirty infants (12.8%) had definite serious bacterial infections (bacteremia: n = 4; bacteremia with urinary tract infections: n = 2; urinary tract infections: n = 24), and 12 infants (5.1%) had possible serious bacterial infections (pneumonia: n = 5; urinary tract infections: n = 7). Mean procalcitonin levels for definite serious bacterial infections (2.21 +/- 3.9 ng/mL) and definite plus possible serious bacterial infections (2.48 +/- 4.6 ng/mL) were significantly higher than that for no serious bacterial infection (0.38 +/- 1.0 ng/mL). The area under the receiver operating characteristic curve was 0.82 for definite serious bacterial infections and 0.76 for definite and possible serious bacterial infections. For identifying definite and possible serious bacterial infections, a cutoff value of 0.12 ng/mL had sensitivity of 95.2%, specificity of 25.5%, negative predictive value of 96.1%, and negative likelihood ratio of 0.19; all cases of bacteremia were identified accurately with this cutoff value.
CONCLUSIONS: Procalcitonin has favorable test characteristics for detecting serious bacterial infections in young febrile infants. Procalcitonin measurements performed especially well in detecting the most serious occult infections.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829791     DOI: 10.1542/peds.2007-3503

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  34 in total

Review 1.  Utility of Procalcitonin as a Biomarker for Sepsis in Children.

Authors:  Kevin J Downes; Julie C Fitzgerald; Scott L Weiss
Journal:  J Clin Microbiol       Date:  2020-06-24       Impact factor: 5.948

Review 2.  Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target.

Authors:  Kenneth L Becker; Richard Snider; Eric S Nylen
Journal:  Br J Pharmacol       Date:  2009-11-27       Impact factor: 8.739

Review 3.  Serum procalcitonin as a diagnostic marker for neonatal sepsis: a systematic review and meta-analysis.

Authors:  Evridiki K Vouloumanou; Eleni Plessa; Drosos E Karageorgopoulos; Elpis Mantadakis; Matthew E Falagas
Journal:  Intensive Care Med       Date:  2011-03-05       Impact factor: 17.440

Review 4.  Inflammation and Nutritional Science for Programs/Policies and Interpretation of Research Evidence (INSPIRE).

Authors:  Daniel J Raiten; Fayrouz A Sakr Ashour; A Catharine Ross; Simin N Meydani; Harry D Dawson; Charles B Stephensen; Bernard J Brabin; Parminder S Suchdev; Ben van Ommen
Journal:  J Nutr       Date:  2015-04-01       Impact factor: 4.798

5.  Cerebrospinal fluid procalcitonin as a biomarker of bacterial meningitis in neonates.

Authors:  Z Reshi; M Nazir; W Wani; M Malik; J Iqbal; S Wajid
Journal:  J Perinatol       Date:  2017-05-25       Impact factor: 2.521

6.  The Yale Observation Scale Score and the Risk of Serious Bacterial Infections in Febrile Infants.

Authors:  Lise E Nigrovic; Prashant V Mahajan; Stephen M Blumberg; Lorin R Browne; James G Linakis; Richard M Ruddy; Jonathan E Bennett; Alexander J Rogers; Leah Tzimenatos; Elizabeth C Powell; Elizabeth R Alpern; T Charles Casper; Octavio Ramilo; Nathan Kuppermann
Journal:  Pediatrics       Date:  2017-06-06       Impact factor: 7.124

7.  Value of Procalcitonin Measurement for Early Evidence of Severe Bacterial Infections in the Pediatric Intensive Care Unit.

Authors:  Andrew J Lautz; Adam C Dziorny; Adam R Denson; Kathleen A O'Connor; Marianne R Chilutti; Rachael K Ross; Jeffrey S Gerber; Scott L Weiss
Journal:  J Pediatr       Date:  2016-08-29       Impact factor: 4.406

8.  Responses to Bacteria, Virus, and Malaria Distinguish the Etiology of Pediatric Clinical Pneumonia.

Authors:  Clarissa Valim; Rushdy Ahmad; Miguel Lanaspa; Yan Tan; Sozinho Acácio; Michael A Gillette; Katherine D Almendinger; Danny A Milner; Lola Madrid; Karell Pellé; Jaroslaw Harezlak; Jacob Silterra; Pedro L Alonso; Steven A Carr; Jill P Mesirov; Dyann F Wirth; Roger C Wiegand; Quique Bassat
Journal:  Am J Respir Crit Care Med       Date:  2016-02-15       Impact factor: 21.405

Review 9.  Early-onset neonatal sepsis.

Authors:  Kari A Simonsen; Ann L Anderson-Berry; Shirley F Delair; H Dele Davies
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

10.  Association of Procalcitonin Value and Bacterial Coinfections in Pediatric Patients With Viral Lower Respiratory Tract Infections Admitted to the Pediatric Intensive Care Unit.

Authors:  John J Kotula; Wayne S Moore; Arun Chopra; Jeffrey J Cies
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Nov-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.